ASXL1 gene mutations, observed in 15–20% of MDS patients, are associated with an inferior prognosis in MDS cases, resulting in a shorter OS and an increased risk of progression to AML [17]. This evidence concerns the gene ASXL1 and myelodysplastic syndrome.